Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 17, 2021 - Issue 12
Submit an article Journal homepage
1,484
Views
0
CrossRef citations to date
0
Altmetric
Short Report

Identification and in vitro validation of neoantigens for immune activation against high-risk pediatric leukemia cells

Satbir Thakura Division of Pediatric Oncology, Alberta Children’s Hospital, Calgary, Alberta, CanadaView further author information
,
Mohit Jaina Division of Pediatric Oncology, Alberta Children’s Hospital, Calgary, Alberta, CanadaView further author information
,
Chunfen Zhanga Division of Pediatric Oncology, Alberta Children’s Hospital, Calgary, Alberta, CanadaView further author information
,
Candice Majora Division of Pediatric Oncology, Alberta Children’s Hospital, Calgary, Alberta, CanadaView further author information
,
Kevin J. Bielamowiczb Division of Hematology/Oncology, Arkansas Children’s Hospital, Little Rock, ArkansasView further author information
,
Norman J. Lacayoc Department of Oncology, Stanford University School of Medicine, Stanford, CaliforniaView further author information
,
Olena Vasked Department of Molecular, Cell and Developmental Biology, University of California Santa Cruz, Santa Cruz, CaliforniaView further author information
,
Victor Lewisa Division of Pediatric Oncology, Alberta Children’s Hospital, Calgary, Alberta, CanadaView further author information
,
Luis Murguia-Favelae Section of Hematology and Immunology, Alberta Children’s Hospital, University of Calgary, Calgary, Alberta, CanadaView further author information
&
Aru Narendrana Division of Pediatric Oncology, Alberta Children’s Hospital, Calgary, Alberta, CanadaCorrespondence[email protected]
View further author information
 show all
Pages 5558-5562 | Received 22 Jul 2021, Accepted 29 Oct 2021, Published online: 29 Nov 2021

References

  • Fang Y, Mo F, Shou J, Wang H, Luo K, Zhang S, Han N, Li H, Ye S, Zhou Z, et al. A pan-cancer clinical study of personalized neoantigen vaccine monotherapy in treating patients with various types of advanced solid tumors. Clin Cancer Res. 2020;26:4511–20.
  • Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–46. doi:10.1038/nrc3670.
  • Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215–29. doi:10.1038/s41571-020-00460-2.
  • Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–82. doi:10.1038/nri.2017.131.
  • Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, Ly A, Lie W-R, Hildebrand WH, Mardis ER, et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015;348(6236):803–08. doi:10.1126/science.aaa3828.
  • Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217–21. doi:10.1038/nature22991.
  • Sahin U, Derhovanessian E, Miller M, Kloke B-P, Simon P, Lower M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017;547(7662):222–26. doi:10.1038/nature23003.
  • Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanovic S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565(7738):240–45. doi:10.1038/s41586-018-0810-y.
  • Majumder S, Shah R, Elias J, Manoharan M, Shah P, Kumari A, Chakraborty P, Kode V, Mistry Y, Coral K, et al. A cancer vaccine approach for personalized treatment of Lynch Syndrome. Sci Rep. 2018;8(1):12122. doi:10.1038/s41598-018-30466-x.
  • Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25(14):1754–60. doi:10.1093/bioinformatics/btp324.
  • Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16):2078–79. doi:10.1093/bioinformatics/btp352.
  • Clarke L, Fairley S, Zheng-Bradley X, Streeter I, Perry E, Lowy E, Tassé A-M, Flicek P. The international Genome sample resource (IGSR): a worldwide collection of genome variation incorporating the 1000 Genomes Project data. Nucleic Acids Res. 2017;45(D1):D854–D9. doi:10.1093/nar/gkw829.
  • Karczewski KJ, Weisburd B, Thomas B, Solomonson M, Ruderfer DM, Kavanagh D, Hamamsy T, Lek M, Samocha KE, Cummings BB, et al. The ExAC browser: displaying reference data information from over 60 000 exomes. Nucleic Acids Res. 2017;45(D1):D840–D5. doi:10.1093/nar/gkw971.
  • Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Ward MH, Kholodov M, Baker J, Phan L, et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res. 2001;29(1):308–11. doi:10.1093/nar/29.1.308.
  • Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: improved Peptide–MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol. 2017;199(9):3360–68. doi:10.4049/jimmunol.1700893.
  • NCT02960230. H3.3K27M peptide vaccine with nivolumab for children with newly diagnosed DIPG and other gliomas.
  • NCT03299309. PEP-CMV in recurrent MEdulloblastoma/MALIGNANT GLIOMA.
  • Campbell BB, Light N, Fabrizio D, Zatzman M, Fuligni F, de Borja R, Davidson S, Edwards M, Elvin JA, Hodel KP, et al. Comprehensive analysis of hypermutation in human cancer. Cell. 2017;171(5):1042–56 e10. doi:10.1016/j.cell.2017.09.048.
  • Majzner RG, Heitzeneder S, Mackall CL. Harnessing the immunotherapy revolution for the treatment of childhood cancers. Cancer Cell. 2017;31(4):476–85. doi:10.1016/j.ccell.2017.03.002.
  • Hutzen B, Paudel SN, Naeimi Kararoudi M, Cassady KA, Lee DA, Cripe TP. Immunotherapies for pediatric cancer: current landscape and future perspectives. Cancer Metastasis Rev. 2019;38(4):573–94. doi:10.1007/s10555-019-09819-z.
  • Chang T-C, Carter RA, Li Y, Li Y, Wang H, Edmonson MN, Chen X, Arnold P, Geiger TL, Wu G, et al. The neoepitope landscape in pediatric cancers. Genome Med. 2017;9(1):78. doi:10.1186/s13073-017-0468-3.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.